The heparins and cancer: Review of clinical trials and biological properties

Vascular Medicine

Volumn 9, Issue 3, 2004, Pages 205-213

  Castelli, Roberto ^a   Porro, Fernando ^a   Tarsia, Paolo ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Cancer; Heparins; Literature research; Thromboembolic diseases; Tumour cells

Indexed keywords

ANTITHROMBIN; BASIC FIBROBLAST GROWTH FACTOR; CHONDROITIN 4 SULFATE; CORTICOSTEROID; DALTEPARIN; DERMATAN SULFATE; FIBRIN; FIBROBLAST GROWTH FACTOR; FLUOROURACIL; GLYCOSAMINOGLYCAN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; HEPARAN SULFATE; HEPARIN; HEPARIN LYASE; LOW MOLECULAR WEIGHT HEPARIN; MITOMYCIN; OLIGOSACCHARIDE; PLACEBO; PLATINUM DERIVATIVE; PROTEINASE; SCATTER FACTOR; TAMOXIFEN; THALIDOMIDE; THROMBIN; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; WARFARIN;

ANGIOGENESIS; ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL PROLIFERATION; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE MODEL; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; IMMUNE SYSTEM; IN VIVO STUDY; LAPAROTOMY; LUNG EMBOLISM; META ANALYSIS; METASTASIS; MORBIDITY; MORTALITY; MYELODYSPLASTIC SYNDROME; MYELOMA; NONHUMAN; PATHOGENESIS; PRIMARY PREVENTION; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; REVIEW; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS PREVENTION;

ANIMALS; CELL PROLIFERATION; CLINICAL TRIALS; ENDOTHELIAL CELLS; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PULMONARY EMBOLISM; THROMBOEMBOLISM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 12344275879     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1191/1358863x04vm566ra     Document Type: Review

References (85)

1. Agnelli G. Venous thromboembolism and cancer: a two way clinical association. Thromb Haemost 1997; 78: 117-20.
2. Sorensen HT, Mellemkjer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998; 338: 1169-73.
3. Baron JA, Gridley G, Weiderpass E, Nyren O, Liner M. Venous thromboembolism and cancer. Lancet 1998; 35: 1077-80.
4. Sproul EE. Carcinoma and venous thrombosis. The frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Cancer 1938; 34: 556-85.
5. Ambrus Jl, Ambrus CM, Mink IB, Picckern JW. Causes of death in cancer patients. J Med 1975; 6: 61-64.
6. Gouin-Thibault L, Samama MM. Laboratory diagnosis of the thrombophilic state in cancer. Semin Thromb Hemost 1999; 25: 167-72.
7. Gouin-Thibault L, Achakar A, Samama MM. The thrombophilic state in cancer patients. Acta Hematol 2001; 106: 33-42.
8. Falanga A, Alessio MG, Donati MB, Barbui T. A new procoagulant in acute leukemia. Blood 1998; 71: 870-75.
9. Falanga A, Consonin R, Marchetti M et al. Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by all-transretinoic acid. Leukemia 1994; 8: 156-59.
10. Donati MB, Gambacorti Passerini C et al. Cancer procoagulant in human tumour cells: evidence from melanoma patients. Cancer Res 1986; 46: 6471-74.
11. Delfini F, Colucci M, de Bellis Vitti G et al. Cancer cell procoagulant: a novel vitamin K dependent activity. Thromb Res 1981; 24: 263-66.
12. Grignani G, Falanga A, Pacchiarini L et al. Human breast and colon carcinomas express cysteine proteinase activities with pro-aggregating and pro-coagulant properties. Int J Cancer 1988; 42: 554-57.
13. Celi A, Lorenzet R, Furie B, Furie BC. Platelet-leukocyte-endothelial cell interaction on the blood vessel wall. Semin Hematol 1997; 34: 327-35.
14. Napoleone M, Di Santo A, Lorenzet R. Monocytes upregulate endothelial cell interaction expression of tissue factor: a role for cell-cell contact and cross talk. Blood 1997; 89: 541-49.
15. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells. Correlation with the malignant phenotype of human breast disease. Nat Med 1996; 2: 209-15.
16. Poggi A, Stella M, Donati MB. The importance of blood cell-vessel wall interactions in tumour metastasis. Baillieres Clin Haematol 1993; 6: 731-52.
17. Falanga A. Mechanisms of hypercoagulation in malignancy and during chemotherapy. Haemostasis 1998; 28(suppl S3): 50-60.
18. Barbui T, Finazzi G, Grassi A. Thrombosis in cancer patients treated with haemopoietic growth factors - a metaanalysis. Thromb Haemost 1996; 75: 368-71.
19. Barbui T, Falanga A. Thalidomide and thrombosis in multiple myeloma. J Thromb Haemost 2003; 3: 421-22,
20. Camba L, Peccatori J, Pescorollo A, Tresoldi M, Corradini P, Bregni M. Thalidomide and thrombosis. Haematologica 2001; 10: 1108-109.
21. Staurer M, Sudmeier I, Stauder R, Gastl G. Thromboembolic events in patients with myelodisplastic syndrome receiving thalidomide with darbepoietin. Br J Haematol 2003; 4: 101-103.
22. Verso M, Agnelli G. Venous thrombosis associated with long term use of central venous catheters in cancer patients. J Clin Oncol 2003; 19: 3655-75.
23. Bona RD. Central line thrombosis in patients with cancer. Curr Op in Pulm Med 2003; 5: 362-65.
24. Clagett GT, Reisch JS. Prevention of thromboembolism in general surgical patients. Results of a meta analysis. Am Surg 1988; 288: 227-40.
25. Svedenssen E, Karwinski B. Prevalence of pulmonary embolism at necroscopy in patients with cancer. J Clin Pathol 1989; 42 805-809.
26. Bussani R, Cosatti C. Pulmonary embolism: epidemiologic analysis of 27 410 autopsies during a 10 years period. Medicina (Firenze) 1990; 10: 40-43.
27. Clarke-Pearson DL, Jelovsek FR, Creasman WT. Thromboembolism complicating surgery for cervical and uterine malignancy: incidence, risk factors, and prophylaxis. Obstet Gynecol 1983; 61: 87-94.
28. Johnson MJ, Sproule MW, Paul J. The prevalence and associate variables of deep venous thrombosis in patients with advanced cancer. Clin Oncol 1999; 11: 105-10.
29. Clagget GP, Anderson FA, Heir J et al. Prevention of thromboembolism. Chest 1995; 34: 312-34.
30. Clagget GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of a meta-analysis. Ann Surg 1998; 208: 227-40.
31. The International Multicentre Trial. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. Lancet 1975; ii: 45-51.
32. Deitcher SR. Cancer and thrombosis: mechanism and treatment. J Thromb Thrombolysis 2003; 16: 21-31.
33. Mousa SA. Low molecular weight heparin in thrombosis and cancer. Thromb Hemost 2004; 1: 25-30.
34. Petralia P, Kakkar AK. Antithrombotic therapy with low molecular weight heparin in cancer patients. Eur J Med Res 2004; 3: 119-24.
35. Mousa SA. Low molecular weight heparin in thrombosis and cancer: emerging links. Cardiovasc Drug Rev 2004; 22: 121-34.
36. Holzheimer RG. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis. Eur J Med Res 2004; 4: 225-39.
37. Bergqvist D, Burmark US, Flordal PA et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 anti Xa units in 2070 patients. Br J Surg 1995; 82: 496-501.
38. Lee AYY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 146-53.
39. Kakkar AK, Levine M, Kadziola Z et al. Low molecular weight heparin, therapy with delta-heparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). Clin Oncol 2004; 22: 1944-48.
40. Bertolesi GE, Lauria de Cidre L, Eryann AM. Growth inhibition in vitro of murine mammary adenocarcinoma cells by heparin and chemically modified heparins. Tumour Biol 1994; 15: 275-83.
41. Zvibel I, Halpern Z, Papa M. Extracellular matrix modulates expression of growth-factor receptors in liver-colonizing colon cancer cells lines. Int J Cancer 1998; 77: 295-301.
42. Lapierre F, Holme K, Lam L et al. Chemical modifications of heparins that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, antitumor and antimetastatic properties. Glycobiology 1996; 6: 355-66.
43. Retik AB, Arons MS, Ketchmann AS, Mantel N. The effects of heparins on primary tumors and metastases. J Surg Res 1962; 11 49-53.
44. Hagmar B, Boyerid B. Disseminating effect of heparin on experimental tumour metastases. Pathol Eur 1969; 4: 274-82.
45. Hagmar B, Norrby K. Evidence for effects of heparin on cell surfaces influencing experimental metastases. Int J Cancer 1970; 5: 72-84.
46. Drago JR, Weed P, Fralisch A. The evaluation of heparin in control of metastasis of Nb rat androgen insensitive prostate carcinoma. Anticancer Res 1984; 4: 171-72.
47. Wood S Jr, Holyoke ED, Yardley JH. Mechanism of metastasis production by blood born cancer cells. Can Cancer Conf 1961; 4 167-233.
48. Lee AE, Rogers LA, Longcroft JM, Jeffery RE. Reduction of metastasis in a murine mammary tumour model by heparin and polyinosinic-polycytidylic acid. Clin Exp Metastasis 1990; 8: 165-71.
49. Lee AE, Rogers LA, Jeffery RE, Longcroft JM. Comparison a metastatic cell lines derived from a murine mammary tumour, and reduction of metastasis by heparin. Clin Exp Metastasis 1988; 6: 463-71.
50. Castellot JJ Jr, Pukac LA, Caleb BL, Wright TC Jr, Karnovsky MJ. Heparin selectively inhibits a protein kinase C-dependent mechanism of cell cycle progression in calf aortic smooth muscle cells. J Cell Biol 1989; 109: 3147-55.
51. Pukac LA, Ottlinger ME, Karnovsky MJ. Heparin suppresses specific second messenger pathways for protooncogene expression in rat vascular smooth muscle cells. J Biol Chem 1992; 267: 3707-11.
52. Ottlinger ME, Pukac LA, Karnovsky MJ. Heparin inhibits mitogen-activated protein kinase activation in intact rat vascular smooth muscle cells. J Biol Chem 1993; 268: 19173-76.
53. Mishra-Gorur K, Castellot JJ Jr. Heparin rapidly and selectively regulates protein tyrosine phosphorylation in vascular smooth muscle cells. J Cell Physiol 1999; 178: 205-15.
54. Imai T, Hirata Y, Marumo F. Heparin inhibits endothelin-1 and protooncogene c-fos gene expression in cultured bovine endothelial cells. J Cardiovasc Pharmacol 1993; 22 (suppl 8): S49-S52.
55. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993; 82: 3253-58.
56. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998; 101: 877-89.
57. Diamond MS, Alon R, Parkos CA, Quinn MT, Springer TA. Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1). J Cell Biol 1995; 130: 1473-82.
58. Weiler JM, Edens RE, Linhardt RJ, Kapelanski DP. Heparin and modified heparin inhibit complement activation in vivo. J Immunol 1992: 148: 3210-15.
59. Linhardt RJ, Rice KG, Kim YS, Engelken JD, Weiler JM. Homogeneous, structurally defined heparin-oligosaccharides with low anticoagulant activity inhibit the generation of the amplification pathway C3 convertase in vitro. J Biol Chem 1988; 263: 13 090-96.
60. Pangburn MK, Atkinson MA, Meri S. Localization of the heparin-binding site on complement factor H. J Biol Chem 1991; 266: 16 847-53.
61. Gorelik E, Bere WW, Herberman RB. Role of NK cells in the antimetastatic effect of anticoagulant drugs. Int J Cancer 1984; 33: 87-94.
62. Senger DR, Perruzzi CA, Feder J, Dvorak HF. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986; 46: 5629-32.
63. Kumar R, Kuniyasu H, Bucana CD, Wilson MR, Fidler IJ. Spatial and temporal expression of angiogenic molecules during tumor growth and progression. Oncol Res 1998; 10: 301-11.
64. Colin S, Jeanny JC, Mascarelli F et al. In vivo involvement of heparan sulfate proteoglycan in the bioavailability, internalization, and catabolism of exogenous basic fibroblast growth factor. Mol Pharmacol 1999; 55: 74-82.
65. D'Amore PA. Capillary growth: a two-cell system. Semin Cancer Biol 1992; 3: 49-56.
66. Folkman J, Weisz PB, Joullie MM, Li WW, Ewing WR. Control of angiogenesis with synthetic heparin substitutes. Science 1989; 243: 1490-93.
67. Soker S, Goldstaub D, Svahn CM, Vlodavsky I, Levi BZ, Neufeld G. Variations in the size and sulfation of heparin modulate the effect of heparin on the binding of VEGF165 to its receptors. Biochem Biophys Res Comm 1994; 203: 1339-47.
68. Lepri A, Benelli U, Bernardini N et al. Effect of low molecular weight heparan sulphate on angiogenesis in the rat cornea after chemical cauterization. J Ocul Pharmacol 1994; 10: 273-80.
69. Jayson GC, Gallagher JT. Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells. Br J Cancer 1997; 75: 9-16.
70. Smorenburg SM, Vink R, Te Lintelo M et al. In vivo treatment of rats with unfractionated heparin (UFH) or low molecular weight heparin (LMWH) does not affect experimentally induced colon carcinoma metastasis. Clin Exp Metastasis 1999; 17: 451-56.
71. Rosen EM, Goldberg ID. Regulation of angiogenesis by scatter factor. EXS 1997; 79: 193-208.
72. Pepper MS. Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 1997; 8: 21-43.
73. Saito H, Tsujitani S et al. The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer 1999; 86: 1455-62.
74. Lyon M, Rushton G, Gallagher JT. The interaction of the transforming growth factor-betas with heparin/heparan sulfate is isoform-specific. J Biol Chem 1997; 272: 18 000-8006.
75. Costantini V, Zacharski LR. Fibrin and cancer. Thromb Haemostasis 1993; 69: 406-14.
76. Van Hinsbergh VW, Koolwijk P, Hanemaaijer R. Role of fibrin and plasminogen activators in repair-associated angiogenesis: in vitro studies with human endothelial cells. EXS 1997; 79: 391-411.
77. Collen A, Smorenburg SM, Peters E. The effects of unfractionated and low molecular weight heparins on microvascular endothelial cell proliferation and formation of capillary-like tubular structures in a fibrin matrix. Cancer Res 2000; 60: 6196-200.
78. Gordon SG, Mielicki WP. Cancer procoagulant: a factor X activator, tumor marker and growth factor from malignant tissue. Blood Coagul Fibrinolysis 1997; 8: 73-86.
79. Rabbani SA. Metalloproteases and urokinase in angiogenesis and tumor progression. In Vivo 1998; 12: 135-42.
80. Au YP, Kenagy RD, Clowes MM, Clowes AW. Mechanisms of inhibition by heparin of vascular smooth muscle cell proliferation and migration. Haemostasis 1993; 23 (suppl 1): 177-82.
81. Folkman J, Langer R, Linhardt RJ, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983; 221 719-25.
82. Van Noorden CJF, Meade-Tollin LM, Bosman FT. Metastasis. Am Sci 1998; 86: 130-41.
83. Smorenburg SM, Hettiarachchi RJK, Vink R, Büller HR. The effects of unfractionated heparin on survival in patients with malignancy - a systematic review. Thromb Haemostasis 1999; 82: 1600-604.
84. Hettiarachchi RJ, Smorenburg SM, Ginsberg J, Levine M, Prins MH, Büller HR. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemostasis 1999; 82: 947-52.
85. Yoshitomi NY, Nakanishi H, Kusano Y et al. Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity. Cancer Lett 2004; 207: 165-74.